Bristol's hepatitis C combo shows high cure rates in trial

04/10/2014 | Reuters

A late-stage trial showed Bristol-Myers Squibb's hepatitis C combination therapy daclatasvir and asunaprevir cured 90% of previously untreated patients with genotype 1b virus after 24 weeks of therapy. The drug also cured 82% of patients who couldn't tolerate interferon and ribavirin, the older standard treatments for the disease. "Not only was the daclatasvir and asunaprevir regimen highly effective among study participants, it was also very well tolerated, even among sicker patients with more advanced liver disease," lead investigator Michael Manns said. The drug combo has already been submitted for FDA review.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR